Review anchor
Gamma-aminobutyric acid receptor subunit alpha-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Gamma-aminobutyric acid receptor subunit alpha-1
CHEMBL1962
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-aminobutyric acid receptor subunit alpha-1 as ChEMBL target CHEMBL1962, mapped to UniProt P14867. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1962
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14867
Gamma-aminobutyric acid receptor subunit alpha-1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Gamma-aminobutyric acid receptor subunit alpha-1 matters
Gamma-aminobutyric acid receptor subunit alpha-1 is reviewed as Gamma-aminobutyric acid receptor subunit alpha-1 (UniProt P14867); Gamma-aminobutyric acid receptor subunit alpha-1 shows late clinical disease relevance led by depressive disorder. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 490 compounds, and 108 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Gamma-aminobutyric acid receptor subunit alpha-1
Gamma-aminobutyric acid receptor subunit alpha-1 Sequence length is 456 aa.
Review this target as Gamma-aminobutyric acid receptor subunit alpha-1, mapped to UniProt P14867. Sequence length is 456 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P14867
Protein
Disease context
depressive disorder
Gamma-aminobutyric acid receptor subunit alpha-1 shows late clinical disease relevance led by depressive disorder. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include INDIPLON.
Start review with depressive disorder because it currently carries late clinical support. Linked drugs include INDIPLON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 12 approved drugs, 490 compounds, and 108 assays for this target. The dominant activity type is KI. CHEMBL3144739 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL3144739 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
12 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit alpha-1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14867, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why depressive disorder is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
490
Total Compounds
108
Total Assays
12
Approved Drugs
IC50: 43.0, KI: 322.0, EC50: 34.0, KD: 22.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3144739
|
10.0 | Kd | — |
|
|
No preferred name
CHEMBL5280240
|
10.0 | Ki | — |
|
|
No preferred name
CHEMBL20042
|
9.5 | Kd | — |
|
|
No preferred name
CHEMBL68684
|
9.4 | Ki | — |
|
|
No preferred name
CHEMBL5771253
|
9.4 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ESZOPICLONE
CHEMBL1522
|
2004 |
|
|
ZOLPIDEM
CHEMBL911
|
1992 |
|
|
FLUMAZENIL
CHEMBL407
|
1991 |
|
|
ALPRAZOLAM
CHEMBL661
|
1981 |
|
|
TRIAZOLAM
CHEMBL646
|
1978 |
|
|
DIAZEPAM
CHEMBL12
|
1963 |
|
|
FLUNITRAZEPAM
CHEMBL13280
|
— |
Source Header